BIIB

Biogen Idec Inc. Q1 2006 Financial Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2006. Biogen Idec operates in oncology, neurology, and immunology, with a portfolio centered on AVONEX (multiple sclerosis), RITUXAN (oncology and rheumatoid arthritis), TYSABRI (multiple sclerosis), and ZEVALIN (oncology). The quarter was marked by significant regulatory progress for TYSABRI, including a unanimous FDA advisory committee vote recommending its reintroduction, and the divestiture of AMEVIVE rights to Astellas in April 2006.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 4% year-over-year. Product sales rose to $406.5 million, driven by AVONEX growth ($393.4 million) and increased RITUXAN copromotion profits ($124.1 million). Royalty revenues declined to $20.6 million due to timing differences in licensee sales.
• Profitability Surge: Net income nearly tripled to $123.0 million. This was driven by a 130% increase in operating income ($173.0 million vs. $75.3 million), primarily due to reduced inventory write-downs and lower facility impairment charges compared to Q1 2005.
• Inventory Write-downs: Inventory write-downs dropped significantly to $3.3 million in Q1 2006 from $41.3 million in Q1 2005. The prior year included a $23.2 million charge related to the voluntary suspension of TYSABRI.
• Accounting Changes: The company adopted SFAS 123(R) effective January 1, 2006, resulting in a $23.6 million pre-tax share-based compensation expense. This adoption included a cumulative effect adjustment that increased net income by $3.8 million.
• Other Income: Other income turned positive at $18.7 million (vs. a loss of $8.9 million in 2005), driven by higher interest income ($23.6 million) due to increased cash levels and lower interest expense following the repurchase of senior notes in 2005.

Outlook, Risks, and Management Commentary

• TYSABRI Reintroduction: Management anticipates FDA action on TYSABRI reintroduction by June 28, 2006, and EMEA action in the summer of 2006. The company has capitalized $11.7 million in TYSABRI inventory costs in anticipation of approval, though risks of permanent withdrawal or restricted labeling remain.
• RITUXAN Expansion: RITUXAN received FDA approval in February 2006 for previously untreated diffuse large B-cell NHL and for rheumatoid arthritis (RA) in combination with methotrexate. Management expects increased sales and marketing expenses in 2006 to support these new indications.
• Strategic Plan: The company continues to execute a strategic plan initiated in late 2005, reducing operating expenses and workforce by approximately 17% (650 positions) to enhance economic flexibility.
• Acquisition: On May 2, 2006, Biogen Idec entered into a merger agreement to acquire Conforma Corporation for an initial $150 million, with up to $100 million in additional milestone payments.
• Litigation: The company faces multiple legal proceedings, including class actions regarding TYSABRI safety disclosures, SEC investigations into TYSABRI suspension, and False Claims Act lawsuits regarding RITUXAN off-label promotion. Management believes these claims lack merit but notes potential financial impact is currently indeterminable.

Investor Verification Checklist

• TYSABRI Regulatory Status: Verify the final FDA and EMEA decisions regarding TYSABRI reintroduction and any associated "black box" warnings or usage restrictions that could impact sales volume.
• Inventory Valuation: Confirm the realizability of the $11.7 million in capitalized TYSABRI inventory and the $45.2 million in AMEVIVE inventory (sold in April 2006) to ensure no future write-downs are required.
• Share-Based Compensation: Review the impact of SFAS 123(R) adoption on future earnings, noting $244.4 million in unrecognized compensation costs to be expensed over 1.6 years.
• Litigation Exposure: Monitor the status of the SEC investigation and False Claims Act lawsuits, as adverse outcomes could result in significant fines or settlements.
• Conforma Merger: Track the closing of the Conforma acquisition and the achievement of development milestones required for the additional $100 million payment.